Navigation Links
Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
Date:9/24/2007

Data Safety Monitoring Board (DSMB) Authorizes Enrollment of Cervical

Patients at Current Highest Authorized Dosage Level

HOPKINTON, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals (Nasdaq: ALSE) today announced that its independent Data Safety Monitoring Board (DSMB) has unanimously authorized expanding the Company's Phase I/IIa clinical trial in acute spinal cord injury (SCI) to allow subjects with cervical SCI to be treated with a 9 mg dose of Cethrin(R). This recommendation is based on the safety analyses of data from thoracic subjects who have been treated at the 9mg dosage level and overall evaluation of safety of the drug in this clinical trial to date.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

In this clinical trial each dose level is first given to thoracic SCI subjects and then, following review by the DSMB, the dose level is extended to cervical subjects. Authorization to administer a 9 mg dose in this clinical trial was given by the U.S. Food and Drug Administration in June 2007 and earlier by Health Canada. Cervical spinal cord injuries occur in the vertebrae of the neck and often result in quadriplegia; thoracic spinal injury occurs in the region of the back between the neck and the pelvis often resulting in paraplegia.

Alseres' DSMB is composed of independent medical and statistical experts who evaluate the safety of the clinical trial being conducted at 9 sites in the US and Canada. The Company expects enrollment in the trial to conclude by the end of 2007.

"The DSMB's recommendation is an important step in the Cethrin clinical plan," c
'/>"/>

SOURCE Alseres Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...che- , , MONTVALE, N.J., Nov. 19 /PRNewswir...aq: MEMY ) today announced that it has achieved .../MEM 3454, its lead alpha-7 nicotinic receptor ago...zophrenia (CIAS). The Company has randomized 212 ...illion payment from its partner Roche. Memory Pha...
(Date:11/18/2008)...arn more, make a donation or send a Christmas Seal...e-USNewswire/ -- Millions will receive Christmas S...can Lung Association. These decorative holiday sta...ting back to 1907 when the Lung Association led ef...Americans alive today have no vivid memories of ho...
(Date:11/18/2008)...USNewswire/ -- Forty-two leading U. S. scientists ...rum to consider cutting-edge innovations that may ...y from outbreaks of dangerous zoonotic diseases, t...hose innovations: , , , , A "Do...etects highly contagious and dangerous zoonotic di...
(Date:11/18/2008)...iagnosed, elderly AML patients , , PRINCETO...ticals today announced that the first patient has ...y of CPX-351 (Cytarabine:Daunorubicin) Liposome In...loid leukemia (AML). , , The first patient ...ical College of Cornell University and New York P...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 1Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 2Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 1Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 2Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 1Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 1Concord Grape Juice Has No Significant Impact on Body Weight 3209 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 3
... of market dynamics offers insights into,what will...to,patients, NEW YORK, May 14, 2007 /PRNewswire-US...pment (TB Alliance), a not-for-profit,product dev...d,development of new TB drugs, today released resu...mics of the global TB drug market,that offers a de...
...pitalization and drug withdrawal, CHICAGO, May 15,...migraine patients and physicians commissioned by t...arris Interactive shows that,20 percent of migrain...ive medications that contain barbiturates or opioi... Drug Administration for the,relief of migraines. ...
Other Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)... Va., Nov. 21 The Gener... following statement today from,GPhA President an...Commission,(FTC) roundtable on "Emerging Health C...e mere fact that the FTC is conducting this roundt...uring that consumers have access to safe and,affo...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2
...umpy old man’, ‘old fogies’ and other such, this i...ersity//. Surprisingly, it’s older people who are ... that people become more positive as they get olde...d to have a "glass empty" view of the world. As ...
...that can keep arteries healthy and prevent heart a...ast one orange// a day could keep cardiac disease ...anones that reduced blood cholesterol levels by 20...on rats, reported the online edition of Daily Mail...
... stress better than those live single, says a stud...r//. Popular perception is that single people have...ws that being in a loving relationship makes it ea...ains of working life, reported online edition of D...
... at Weill Cornell Medical College could prove a po...The compound, called SS31, is able to cross the bl...molecule recently linked to stroke-related tissue ...s, we found that exposing mice to SS31 after an in...
Other Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: